A novel experimental drug may soon change the outlook for patients battling hard-to-treat hypertension.

AstraZeneca’s baxdrostat, a first-in-class therapy, has demonstrated 24-hour blood pressure control, including during early morning hours when the risk of heart attack and stroke is at its peak.

In a large international clinical trial conducted across 79 countries, baxdrostat significantly reduced blood pressure in individuals whose hypertension remained dangerously high despite multiple medications.

Results from the Bax24 Phase III trial were unveiled two days ago at the American Heart Association Scientific Sessions.

Baxdrostat works by selectively blocking aldosterone, a hormone that raises blood pressure and contributes to heart and kidney disease.

“By targeting aldosterone di

See Full Page